A Multicenter Assessment of ALD403 in Chronic Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

665

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

November 30, 2016

Conditions
Migraine Disorders
Interventions
BIOLOGICAL

ALD403

BIOLOGICAL

Placebo

Trial Locations (92)

2031

Research Site, Sydney

2856

Research Site, Christchurch

3004

Research Site, Melbourne

3050

Research Site, Melbourne

3204

Research Site, Hamilton

6009

Research Site, Perth

8963

Research Site, Auckland

10019

Research Site, New York

10461

Research Site, The Bronx

11235

Research Site, Brooklyn

12208

Research Site, Albany

13760

Research Site, Endwell

14226

Research Site, Amherst

14609

Research Site, Rochester

19090

Research Site, Willow Grove

19107

Research Site, Philadelphia

21310

Research Site, Boston

23226

Research Site, Richmond

23454

Research Site, Virginia Beach

27103

Research Site, Winston-Salem

27518

Research Site, Cary

29464

Research Site, Mt. Pleasant

30022

Research Site, Atlanta

30342

Research Site, Atlanta

32256

Research Site, Jacksonville

32607

Research Site, Gainesville

32801

Research Site, Orlando

32806

Research Site, Orlando

33009

Research Site, Hallandale

33144

Research Site, Miami

33161

Research Site, North Miami

33173

Research Site, Miami

33606

Research Site, Tampa

35801

Research Site, Huntsville

36608

Research Site, Mobile

37421

Research Site, Chattanooga

38119

Research Site, Memphis

40207

Research Site, Louisville

43213

Research Site, Columbus

44195

Research Site, Cleveland

44718

Research Site, Canton

45255

Research Site, Cincinnati

45424

Research Site, Dayton

47714

Research Site, Evansville

48104

Research Site, Ann Arbor

60607

Research Site, Chicago

60640

Research Site, Chicago

61761

Research Site, Normal

63141

Research Site, St Louis

65807

Research Site, Springfield

66206

Research Site, Prairie Village

67207

Research Site, Wichita

68134

Research Site, Omaha

70115

Research Site, New Orleans

71105

Research Site, Shreveport

71901

Research Site, Hot Springs

72211

Research Site, Little Rock

73116

Research Site, Oklahoma City

75231

Research Site, Dallas

76104

Research Site, Fort Worth

77058

Research Site, Houston

78705

Research Site, Austin

80210

Research Site, Denver

80918

Research Site, Colorado Springs

84058

Research Site, Orem

84109

Research Site, Salt Lake City

85027

Research Site, Phoenix

85259

Research Site, Scottsdale

87102

Research Site, Albuquerque

90036

Research Site, Los Angeles

90404

Research Site, Santa Monica

90806

Reserach Site, Long Beach

91436

Research Site, Encino

92108

Research Site, San Diego

92801

Research Site, Anaheim

93003

Research Site, Ventura

94102

Research Site, San Francisco

94305

Research Site, Stanford

94612

Research Site, Oakland

97239

Research Site, Portland

98007

Research Site, Bellevue

98105

Research Site, Seattle

98405

Research Site, Tacoma

06905

Research Site, Stamford

06708

Research Site, Waterbury

02301

Research Site, Brockton

02740

Research Site, New Bedford

02472

Research Site, Watertown

08540

Research Site, Princeton

0112

Research Site, Tbilisi

0160

Research Site, Tbilisi

0186

Research Site, Tbilisi

Sponsors
All Listed Sponsors
lead

Alder Biopharmaceuticals, Inc.

INDUSTRY

NCT02275117 - A Multicenter Assessment of ALD403 in Chronic Migraine | Biotech Hunter | Biotech Hunter